Switching from statin monotherapy to ezetimibe/simvastatin or rosuvastatin modifies the relationships between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients at high risk of coronary disease

Clinical Biochemistry

Volumn 44, Issue 8-9, 2011, Pages 627-634

  Vaverkova, Helena ^a   Farnier, Michel ^b   Averna, Maurizio ^c   Missault, Luc ^d   Viigimaa, Margus ^e   Dong, Qian ^f   Shah, Arvind ^f   Johnson Levonas, Amy O ^f   Brudi, Philippe ^g  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b Point Medical   (France)

^c UNIVERSITY OF PALERMO   (Italy)

^d General Hospital St Jan   (Belgium)

^e TALLINN UNIVERSITY OF TECHNOLOGY   (Estonia)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Merck Medical Affairs   (United States)

Author keywords

Apolipoprotein B; Correlation; Ezetimibe simvastatin; Low density lipoprotein cholesterol; Non high density lipoprotein cholesterol; Rosuvastatin

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; PRIORITY JOURNAL;

AGED; APOLIPOPROTEINS B; AZETIDINES; CHOLESTEROL; CORONARY DISEASE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRIMIDINES; SIMVASTATIN; SULFONAMIDES;

EID: 79955795316     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.02.008     Document Type: Article

References (37)

1. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
2. Arsenault B.J., Rana J.S., Stroes E.S., et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009, 55:35-41.
3. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921.
4. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 2001, 88:265-269.
5. Ballantyne C.M., Bertolami M., Hernandez Garcia H.R., et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J 2006, 151:975-979.
6. Ballantyne C.M., Raichlen J.S., Cain V.A. Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using Rosuvastatin) trial. J Am Coll Cardiol 2008, 52:626-632.
7. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 2006, 259:247-258.
8. Brunzell J.D., Davidson M., Furberg C.D., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diab Care 2008, 31:811-822.
9. Charlton-Menys V., Betteridge D.J., Colhoun H., et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem 2009, 55:473-480.
10. Contois J.H., McConnell J.P., Sethi A.A., et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009, 55:407-419.
11. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. J Clin Lipidol 2007, 1:583-592.
12. Farnier M., Averna M., Missault L., et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-the IN-CROSS study. Int J Clin Pract 2009, 63:547-559.
13. Finely P. Nephelometry: principles and clinical laboratory applications. Lab Manage 2011, 20:34.
14. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
15. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
16. Graham I., Atar D., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007, 14(Suppl 2):E1-E40.
17. Griffin B.A., Minihane A.M., Furlonger N., et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci (Lond) 1999, 97:269-276.
18. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
19. Kastelein J.J., van der Steeg W.A., Holme I., et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation 2008, 117:3002-3009.
20. Kiss Z., Simo I.E., Ooi T.C., Meuffels M., Hindmarsh J.T. Presence of unsedimented precipitate in visually non-turbid supernates in the heparin-manganese method for HDL-cholesterol quantitation. Clin Biochem 1986, 19:209-211.
21. Krauss R.M. Lipids and lipoproteins in patients with type 2 diabetes. Diab Care 2004, 27:1496-1504.
22. McQueen M.J., Hawken S., Wang X., et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 2008, 372:224-233.
23. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med 1989, 9:105-135.
24. Pischon T., Girman C.J., Sacks F.M., et al. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 2005, 112:3375-3383.
25. Ridker P.M., Rifai N., Cook N.R., Bradwin G., Buring J.E. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005, 294:326-333.
26. Sacks F.M. The apolipoprotein story. Atheroscler Suppl 2006, 7:23-27.
27. Simes R.J., Marschner I.C., Hunt D., et al. Relationship between lipid levels and clinical outcomes in the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 2002, 105:1162-1169.
28. Simon A., Chironi G., Gariepy J., Del Pino M., Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005, 179:339-344.
29. Smith S.C., Allen J., Blair S.N., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113:2363-2372.
30. Sniderman A. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL lowering therapy: implications to clinical practice. J Clin Lipidol 2008, 2:36-42.
31. Sniderman A., Shapiro S., Marpole D., et al. Association of coronary atherosclerosis with hyperapobetalipoproteinemia [increased protein but normal cholesterol levels in human plasma low density (beta) lipoproteins]. Proc Natl Acad Sci USA 1980, 77:604-608.
32. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003, 361:777-780.
33. Sniderman A.D., St.Pierre A.C., Cantin B., et al. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003, 91:1173-1177.
34. Talmud P.J., Hawe E., Miller G.J., Humphries S.E. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol 2002, 22:1918-1923.
35. Walldius G., Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004, 255:188-205.
36. Walldius G., Jungner I., Holme I., et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
37. Warnick G.R., Albers J.J. A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978, 19:65-76.